What question did this study set out to answer?

This research aims to analyze access pathways and barriers for ctDNA-based MRD testing in solid tumors.

March 21, 2026Open Access

371P System dynamics analysis of access pathways and hurdles for ctDNA-based MRD testing in solid tumors

Puntos clave

This research aims to analyze access pathways and barriers for ctDNA-based MRD testing in solid tumors.
Observational study design
Assessment of FHC ratios in patients with solid tumors
Identification of thresholds for total FHC scores
Selection criteria for germline mutation testing
Mean FHC ratio was 0.43, with a median of 0.40
90th percentile threshold was identified as 0.89
Only 9.8% of patients met the criteria for the 90th percentile
24.7% of patients fit the 75th percentile threshold

Resumen

Table: 369P 336 FHC ratio 1 st degree Mean 0.39 (0-1.44)Median 0.35 (0-0.61)FHC ratio 2 nd degree Mean 0.03 (0-0.25)Median 0 (0-0.06)FHC ratio 3 rd degree Mean 0.01 (0-0.15)Median 0 (0-0.02)Total FHC score Mean 0.43 (0-1.48)Median 0.40 (0.12-0.67) 90 th percentile threshold 0.89 (0.62-0.96) 75 th percentile threshold 0.67 (0.62-0.71)Patients included 90 th percentile 33 (9.8%)Patients included 75 th percentile 83 (24.7%) Conclusions:The observational phase of the study shows the potential utility of FHC in selecting NSCLC patients for germline mutation testing.Clinical trial identification: NCT06196424.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo